XANOMELINE AND TROSPIUM

Authors

  • Mekala Anusha Pharm-D 4th Year, Malla Reddy College of Pharmacy, Dhulapally, Secunderabad, Telangana, 500100 (Affiliated to Osmania University).
  • Nikitha Pharm-D 4th Year, Malla Reddy College of Pharmacy, Dhulapally, Secunderabad, Telangana, 500100 (Affiliated to Osmania University).
  • Sushma Goud Pharm-D 4th Year, Malla Reddy College of Pharmacy, Dhulapally, Secunderabad, Telangana, 500100 (Affiliated to Osmania University).

Keywords:

xanomeline, schizophrenia, Alzheimer's, trospium

Abstract

The cholinergic agonist xanomeline was first investigated for schizophrenia and Alzheimer's disease, but research was halted because of cholinergic adverse effects. Its usage in conjunction with trospium, a peripheral cholinergic antagonist, has recently been investigated in schizophrenia patients. Constipation, dry mouth, and nausea are examples of cholinergic side effects that may be lessened by this combination. Xanomeline has M1/M4 agonist activity and evidence from early studies is promising. The fixed-dose combination of xanomeline and trospium will be marketed as Cobenfy (KarXT) and results from phase III trials show xanomeline-trospium in phase III trials significantly reduce symptoms in schizophrenia with positive results backed by a strong efficacy profile and overall acceptable safety data.

Dimensions

Published

2025-11-28

Issue

Vol. 15 No. 4 (2025): 2025 Volume -15 - Issue 4

Section

Articles
Copyright & Licensing
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.